Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 27:13:3051-3067.
doi: 10.2147/DDDT.S221437. eCollection 2019.

Ketamine and depression: a narrative review

Alexandrine Corriger  1   2 , Gisèle Pickering  1   2
Affiliations
Review

Ketamine and depression: a narrative review

Alexandrine Corriger et al. Drug Des Devel Ther. .

Abstract

Depression is the third leading cause of disability in the world. Depressive symptoms may be reduced within several weeks after the start of conventional antidepressants, but treatment resistance concerns one-third of patients who fail to achieve recovery. Over the last 20 years, ketamine, an antagonist of the N-methyl-D-aspartate receptor, has been described to have antidepressant properties. A literature review was conducted through an exhaustive electronic search. It was restricted to Cochrane reviews, meta-analyses, and randomized controlled trials (RCTs) of ketamine for major depressive disorder and/or bipolar disorder. This review included two Cochrane reviews, 14 meta-analyses and 15 trials. Ketamine was studied versus placebo, versus other comparators and as an anesthetic adjuvant before electroconvulsive therapy. In 14 publications, ketamine provided a rapid antidepressant effect with a maximum efficacy reached at 24 hrs. Its effect lasted for 1-2 weeks after infusion, but a longer-term effect is little reported. Ketamine does not seem to improve depressive symptoms at the end of electroconvulsive sessions. Safety and tolerability profiles with ketamine at low single dose are generally good in depressed patients. However, there is a lack of data concerning ketamine with repeated administration at higher doses. The clinical use of ketamine is increasing. Intranasal (S)-ketamine has recently been approved for depression by the Food and Drug Administration. It could be a promising treatment in depressed patients with suicidal ideation. Collectively, the level of proof of efficacy remains low and more RCTs are needed to explore efficacy and safety issues of ketamine in depression.

Keywords: bipolar depression; depression; efficacy; ketamine; major depressive disorder; suicide.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no competing financial or non-financial interests in this work.

Figures

Figure 1
Figure 1
Flowchart of the literature review process. Abbreviations: ECT, electroconvulsive therapy; RCT, randomized controlled trial.
Figure 2
Figure 2
(A) Ketamine efficacy with time (versus placebo or other comparators). (B) Ketamine efficacy with the number of electroconvulsive therapies (ECT) (ketamine given as an anesthetic adjuvant pre-ECT). Notes: Numbers represent references. Bold red: Cochrane review; bold purple: meta-analyses; others: randomized controlled trials.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization. Depression; 2018. Available from: https://www.who.int/news-room/fact-sheets/detail/depression. Accessed June6, 2019
    1. Ishak WW, Greenberg JM, Cohen RM. Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the individual burden of illness index for depression (IBI-D). J Affect Disord. 2013;151:59–65. doi:10.1016/j.jad.2013.08.002 - DOI - PMC - PubMed
    1. Collins PY, Patel V, Joestl SS, et al. Grand challenges in global mental health. Nature. 2011;475:27–30. doi:10.1038/475027a - DOI - PMC - PubMed
    1. Vandeleur CL, Fassassi S, Castelao E, et al. Prevalence and correlates of DSM-5 major depressive and related disorders in the community. Psychiatry Res. 2017;250:50–58. doi:10.1016/j.psychres.2017.01.060 - DOI - PubMed
    1. Merikangas KR, Jin R, He J-P, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68:241–251. doi:10.1001/archgenpsychiatry.2011.12 - DOI - PMC - PubMed

MeSH terms